{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04677114",
            "orgStudyIdInfo": {
                "id": "60903"
            },
            "secondaryIdInfos": [
                {
                    "id": "1R01DA048892",
                    "type": "NIH",
                    "link": "https://reporter.nih.gov/quickSearch/1R01DA048892"
                }
            ],
            "organization": {
                "fullName": "University of Kentucky",
                "class": "OTHER"
            },
            "briefTitle": "Integrated Outpatient Treatment of Opioid Use Disorder and Severe Injection Related Infections",
            "officialTitle": "Integrated Outpatient Treatment of Opioid Use Disorder and Severe Injection Related Infections",
            "acronym": "BOPAT",
            "therapeuticArea": [
                "Other"
            ],
            "study": "integrated-outpatient-treatment-of-opioid-use-disorder-and-severe-injection-related-infections"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-11",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-03-16",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-08-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-12-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2020-12-13",
            "studyFirstSubmitQcDate": "2020-12-18",
            "studyFirstPostDateStruct": {
                "date": "2020-12-21",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-11-02",
            "lastUpdatePostDateStruct": {
                "date": "2023-11-03",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR_INVESTIGATOR",
                "investigatorFullName": "Laura Fanucchi",
                "investigatorTitle": "Associate Professor",
                "investigatorAffiliation": "University of Kentucky"
            },
            "leadSponsor": {
                "name": "Laura Fanucchi",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "National Institute on Drug Abuse (NIDA)",
                    "class": "NIH"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": true
        },
        "descriptionModule": {
            "briefSummary": "This study will assess the efficacy of an integrated outpatient treatment model for persons with opioid use disorder and injection related infections. The investigators hypothesize that outpatient antibiotic treatment coupled with comprehensive treatment for opioid use disorder will demonstrate a safe and effective way to manage patients. Results could improve the current protocols for the treatment of individuals with opioid use disorder and severe infections."
        },
        "conditionsModule": {
            "conditions": [
                "Drug Use",
                "Opioid-use Disorder"
            ],
            "keywords": [
                "buprenorphine",
                "outpatient",
                "parenteral",
                "antibiotic",
                "OPAT",
                "injection",
                "infectious endocarditis",
                "injection-related",
                "infection"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 90,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Outpatient Parenteral Antibiotic Therapy (OPAT)",
                    "type": "EXPERIMENTAL",
                    "description": "Patients with opioid use disorder (OUD) and severe, injection-related infections (SIRI) will be treated with buprenorphine and be discharged with outpatient parenteral antibiotic therapy (OPAT).",
                    "interventionNames": [
                        "Drug: Buprenorphine and Outpatient Parenteral Antibiotic Therapy"
                    ]
                },
                {
                    "label": "Treatment as Usual (TAU)",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Patients with OUD and severe, injection-related infections (SIRI) will receive usual care.",
                    "interventionNames": [
                        "Drug: Buprenorphine and standard of care antibiotic treatment"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Buprenorphine and Outpatient Parenteral Antibiotic Therapy",
                    "description": "Participants will be complete IV antibiotics with OPAT. All participants will receive buprenorphine treatment of OUD.",
                    "armGroupLabels": [
                        "Outpatient Parenteral Antibiotic Therapy (OPAT)"
                    ],
                    "otherNames": [
                        "Suboxone or Sublocade"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Buprenorphine and standard of care antibiotic treatment",
                    "description": "All participants will receive treatment of OUD and the infection per usual clinical care.",
                    "armGroupLabels": [
                        "Treatment as Usual (TAU)"
                    ],
                    "otherNames": [
                        "Suboxone or Sublocade"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Illicit Opioid Use",
                    "description": "Proportion of urine samples with negative urine drug screen for illicit opioid use",
                    "timeFrame": "12 weeks after hospital discharge"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Completion of Recommended IV Antibiotic Therapy",
                    "description": "Proportion of patients who completed of recommended IV antibiotic therapy",
                    "timeFrame": "up to 12 weeks (duration of IV antibiotic course as determined by treating physician)"
                },
                {
                    "measure": "Abstinence From Illicit Opioid",
                    "description": "Self-reported number of days of illicit opioid abstinence",
                    "timeFrame": "12 weeks after hospital discharge"
                },
                {
                    "measure": "Abstinence from Injection Drug Use",
                    "description": "Self-reported number of days without injection use of any drug",
                    "timeFrame": "12 weeks after hospital discharge"
                },
                {
                    "measure": "Outpatient Treatment Retention",
                    "description": "Number of days patients remain in treatment.",
                    "timeFrame": "12 weeks after hospital discharge"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* have opioid use disorder\n* have a severe injection related infection requiring antibiotics\n* willing to accept buprenorphine treatment\n* anticipated to be discharged home\n* require IV antibiotic therapy\n\nExclusion Criteria:\n\n* stroke or cerebral mycotic aneurysms preventing aortic or mitral valve surgery\n* fungal valve IE\n* requiring in-patient rehabilitation\n* current pregnancy\n* hypersensitivity or allergy to buprenorphine\n* class III or IV heart failure\n* end-stage liver or renal disease\n* any condition that may prevent the volunteer from safely participating in the study\n* self-report of desire to inject into the PICC line\n* pending legal action that could interfere with study participation\n* unsafe or unstable environment precluding safe administration of IV antibiotics\n* living more than a 60 minute drive outside of Lexington, KY",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "99 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Laura Fanucchi",
                    "role": "CONTACT",
                    "phone": "859-323-1982",
                    "email": "laura.fanucchi@uky.edu"
                }
            ],
            "locations": [
                {
                    "facility": "University of Kentucky",
                    "status": "RECRUITING",
                    "city": "Lexington",
                    "state": "Kentucky",
                    "zip": "40515",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Andrea N McNaughton",
                            "role": "CONTACT",
                            "phone": "859-218-0714"
                        },
                        {
                            "name": "Connor M VanMeter",
                            "role": "CONTACT",
                            "phone": "859-562-0566"
                        },
                        {
                            "name": "Laura C Fanucchi, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.98869,
                        "lon": -84.47772
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "pmid": "35847566",
                    "type": "BACKGROUND",
                    "citation": "Fanucchi LC, Murphy SM, Surratt H, Kapadia SN, Walsh SL, Grubbs JA, Thornton AC, Nuzzo P, Lofwall MR. Design and protocol of the Buprenorphine plus Outpatient Parenteral Antimicrobial Therapy (B-OPAT) study: a randomized clinical trial of integrated outpatient treatment of opioid use disorder and severe, injection-related infections. Ther Adv Infect Dis. 2022 Jul 11;9:20499361221108005. doi: 10.1177/20499361221108005. eCollection 2022 Jan-Dec."
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000007239",
                    "term": "Infections"
                },
                {
                    "id": "D000009293",
                    "term": "Opioid-Related Disorders"
                },
                {
                    "id": "D000019966",
                    "term": "Substance-Related Disorders"
                }
            ],
            "ancestors": [
                {
                    "id": "D000079524",
                    "term": "Narcotic-Related Disorders"
                },
                {
                    "id": "D000064419",
                    "term": "Chemically-Induced Disorders"
                },
                {
                    "id": "D000001523",
                    "term": "Mental Disorders"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M10283",
                    "name": "Infections",
                    "asFound": "Infection",
                    "relevance": "HIGH"
                },
                {
                    "id": "M6368",
                    "name": "Communicable Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M7858",
                    "name": "Endocarditis",
                    "relevance": "LOW"
                },
                {
                    "id": "M7860",
                    "name": "Endocarditis, Subacute Bacterial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12244",
                    "name": "Opioid-Related Disorders",
                    "asFound": "Opioid Use Disorder",
                    "relevance": "HIGH"
                },
                {
                    "id": "M21837",
                    "name": "Substance-Related Disorders",
                    "asFound": "Opioid Use Disorder",
                    "relevance": "HIGH"
                },
                {
                    "id": "M2057",
                    "name": "Narcotic-Related Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M30302",
                    "name": "Chemically-Induced Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M4815",
                    "name": "Mental Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M14473",
                    "name": "Psychotic Disorders",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC01",
                    "name": "Infections"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "BC14",
                    "name": "Heart and Blood Diseases"
                },
                {
                    "abbrev": "BC25",
                    "name": "Substance Related Disorders"
                },
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000000900",
                    "term": "Anti-Bacterial Agents"
                },
                {
                    "id": "D000000904",
                    "term": "Antibiotics, Antitubercular"
                },
                {
                    "id": "D000002047",
                    "term": "Buprenorphine"
                },
                {
                    "id": "D000069479",
                    "term": "Buprenorphine, Naloxone Drug Combination"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000890",
                    "term": "Anti-Infective Agents"
                },
                {
                    "id": "D000000995",
                    "term": "Antitubercular Agents"
                },
                {
                    "id": "D000000701",
                    "term": "Analgesics, Opioid"
                },
                {
                    "id": "D000009294",
                    "term": "Narcotics"
                },
                {
                    "id": "D000002492",
                    "term": "Central Nervous System Depressants"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000000700",
                    "term": "Analgesics"
                },
                {
                    "id": "D000018689",
                    "term": "Sensory System Agents"
                },
                {
                    "id": "D000018373",
                    "term": "Peripheral Nervous System Agents"
                },
                {
                    "id": "D000009292",
                    "term": "Narcotic Antagonists"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4033",
                    "name": "Analgesics, Opioid",
                    "relevance": "LOW"
                },
                {
                    "id": "M4222",
                    "name": "Anti-Bacterial Agents",
                    "asFound": "Peripheral",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4224",
                    "name": "Antibiotics, Antitubercular",
                    "asFound": "Peripheral",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5317",
                    "name": "Buprenorphine",
                    "asFound": "Attention",
                    "relevance": "HIGH"
                },
                {
                    "id": "M447",
                    "name": "Buprenorphine, Naloxone Drug Combination",
                    "asFound": "Extracted",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4311",
                    "name": "Antitubercular Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M12221",
                    "name": "Naloxone",
                    "relevance": "LOW"
                },
                {
                    "id": "M4214",
                    "name": "Anti-Infective Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4032",
                    "name": "Analgesics",
                    "relevance": "LOW"
                },
                {
                    "id": "M12245",
                    "name": "Narcotics",
                    "relevance": "LOW"
                },
                {
                    "id": "M12243",
                    "name": "Narcotic Antagonists",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Analg",
                    "name": "Analgesics"
                },
                {
                    "abbrev": "CNSDep",
                    "name": "Central Nervous System Depressants"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                },
                {
                    "abbrev": "NarcAntag",
                    "name": "Narcotic Antagonists"
                }
            ]
        }
    },
    "hasResults": false
}